FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282918650> ?p ?o ?g. }

• W4282918650 endingPage "5513" @default.
• W4282918650 startingPage "5513" @default.
• W4282918650 abstract "Abstract Despite success in hematologic malignancies, chimeric antigen receptor (CAR) T cells have been less effective in solid tumors, in part because of the heterogeneous expression of the CAR-specific target antigen (1° Ag) found within the tumor mass. In combination with a CAR, bispecific T cell engagers (BiTEs) can target additional tumor antigens (2° Ag) while engaging CD3 signaling molecules on T cells, providing a unique way to address tumor heterogeneity, mitigate antigen escape and further potentiate durable effector function. However, in generating off-the-shelf universal CAR-T and NK cells, a combination strategy is not feasible as neither modified cell product is compatible to specifically engage with a BiTE. In developing allogeneic CAR-T cells, the T cell receptor (TCR) surface expression must be eliminated to prevent graft versus host disease, but the absence of surface TCR expression leads to loss of surface CD3 expression and BiTE compatibility. Similarly, NK cells naturally lack TCR expression and have no surface CD3 molecules for BiTE engagement. Here we discuss the development of a novel chimeric CD3ε fusion receptor (CD3-CFR) with a modified transmembrane and endodomain enabling surface expression in TCR-less T or NK cells, allowing for a novel combinatorial solution between universal CAR-T or NK cells with BiTEs in an allogeneic setting. CD3-CFR signal transduction was initially investigated in TRAC knockout NFAT reporter (T-KO) Jurkat cells engineered with CD3-CFR and co-cultured with EpCAM+ target cells. When soluble EpCAM-BiTE was added to the co-culture, the observed 6.9-fold increase in NFAT activity indicated successful engagement associated with the interaction of CD3-CFR, target cells and the BiTE. CD3-CFR T-KO Jurkat cells were further modified to secrete the EpCAM-BiTE and showed increased NFAT activity, demonstrating the feasibility of self-secreting BiTE-mediated targeting through CD3-CFR signaling. We next engineered CD3-CFR expressing iPSC-derived CAR-T (iT) cells to show preserved T cell differentiation kinetics and maintained CAR activity against 1° Ag positive targets (&gt;90% cytolysis). Importantly, while CAR-iT cells showed only background lysis of 1° Ag negative tumor cells, CD3-CFR+ CAR-iT cells were able to lyse ~99% of 1° Ag negative tumor cells with the addition of soluble EpCAM-BiTE targeting the 2° Ag. When CD3-CFR+ CAR-iT cells were further engineered to secrete the EpCAM-BiTE, CD3-CFR+ BiTE+ CAR-iT cells demonstrated superior killing of heterogenous tumors compared to CD3-CFR+ BiTE- CAR-iT cells (70% vs. 5% cytolysis). Taken together these data demonstrate for the first time that CD3 expression and BiTE engagement can be combined in a universal iPSC-derived CAR-iT cell product to overcome antigen heterogeneity and enhance efficacy in solid tumor settings. Citation Format: Eigen Peralta, Dan Lu, Mark Landon, Hui-Yi Chu, Amit Mehta, Philip Chu, Alec Witty, Tom Lee, Bahram Valamehr. Chimeric CD3 fusion receptors expressed on iPSC-derived universal TCR-less CAR-T and -NK cells synergize with bispecific engagers to enhance antitumor activity and limit antigen escape [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5513." @default.
• W4282918650 created "2022-06-16" @default.
• W4282918650 creator A5003908929 @default.
• W4282918650 creator A5008300500 @default.
• W4282918650 creator A5011946503 @default.
• W4282918650 creator A5016444406 @default.
• W4282918650 creator A5070964738 @default.
• W4282918650 creator A5073847745 @default.
• W4282918650 creator A5081697560 @default.
• W4282918650 creator A5086861101 @default.
• W4282918650 creator A5091390704 @default.
• W4282918650 date "2022-06-15" @default.
• W4282918650 modified "2023-10-07" @default.
• W4282918650 title "Abstract 5513: Chimeric CD3 fusion receptors expressed on iPSC-derived universal TCR-less CAR-T and -NK cells synergize with bispecific engagers to enhance antitumor activity and limit antigen escape" @default.
• W4282918650 doi "https://doi.org/10.1158/1538-7445.am2022-5513" @default.
• W4282918650 hasPublicationYear "2022" @default.
• W4282918650 type Work @default.
• W4282918650 citedByCount "0" @default.
• W4282918650 crossrefType "journal-article" @default.
• W4282918650 hasAuthorship W4282918650A5003908929 @default.
• W4282918650 hasAuthorship W4282918650A5008300500 @default.
• W4282918650 hasAuthorship W4282918650A5011946503 @default.
• W4282918650 hasAuthorship W4282918650A5016444406 @default.
• W4282918650 hasAuthorship W4282918650A5070964738 @default.
• W4282918650 hasAuthorship W4282918650A5073847745 @default.
• W4282918650 hasAuthorship W4282918650A5081697560 @default.
• W4282918650 hasAuthorship W4282918650A5086861101 @default.
• W4282918650 hasAuthorship W4282918650A5091390704 @default.
• W4282918650 hasConcept C114684123 @default.
• W4282918650 hasConcept C147483822 @default.
• W4282918650 hasConcept C167672396 @default.
• W4282918650 hasConcept C179464577 @default.
• W4282918650 hasConcept C19317047 @default.
• W4282918650 hasConcept C203014093 @default.
• W4282918650 hasConcept C2776090121 @default.
• W4282918650 hasConcept C3875195 @default.
• W4282918650 hasConcept C502942594 @default.
• W4282918650 hasConcept C86803240 @default.
• W4282918650 hasConcept C8891405 @default.
• W4282918650 hasConcept C95444343 @default.
• W4282918650 hasConceptScore W4282918650C114684123 @default.
• W4282918650 hasConceptScore W4282918650C147483822 @default.
• W4282918650 hasConceptScore W4282918650C167672396 @default.
• W4282918650 hasConceptScore W4282918650C179464577 @default.
• W4282918650 hasConceptScore W4282918650C19317047 @default.
• W4282918650 hasConceptScore W4282918650C203014093 @default.
• W4282918650 hasConceptScore W4282918650C2776090121 @default.
• W4282918650 hasConceptScore W4282918650C3875195 @default.
• W4282918650 hasConceptScore W4282918650C502942594 @default.
• W4282918650 hasConceptScore W4282918650C86803240 @default.
• W4282918650 hasConceptScore W4282918650C8891405 @default.
• W4282918650 hasConceptScore W4282918650C95444343 @default.
• W4282918650 hasIssue "12_Supplement" @default.
• W4282918650 hasLocation W42829186501 @default.
• W4282918650 hasOpenAccess W4282918650 @default.
• W4282918650 hasPrimaryLocation W42829186501 @default.
• W4282918650 hasRelatedWork W1509585756 @default.
• W4282918650 hasRelatedWork W1970741281 @default.
• W4282918650 hasRelatedWork W1971670502 @default.
• W4282918650 hasRelatedWork W2015090226 @default.
• W4282918650 hasRelatedWork W2139160256 @default.
• W4282918650 hasRelatedWork W2392029702 @default.
• W4282918650 hasRelatedWork W2398881750 @default.
• W4282918650 hasRelatedWork W2969531067 @default.
• W4282918650 hasRelatedWork W3004207027 @default.
• W4282918650 hasRelatedWork W4294193037 @default.
• W4282918650 hasVolume "82" @default.
• W4282918650 isParatext "false" @default.
• W4282918650 isRetracted "false" @default.
• W4282918650 workType "article" @default.